<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[46, 62] patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen.<br>[66, 71] Patients with bidimensionally measurable disease<br>[163, 165] 226 patients<br></td>
<td width=33%>
[16, 21] advanced epithelial ovarian carcinoma.<br>[31, 32] patients<br>[44, 62] paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen.<br>[66, 71] Patients with bidimensionally measurable disease<br>[160, 165] A total of 226 patients<br></td>
<td width=33%>
[16, 21] advanced epithelial ovarian carcinoma.<br>[31, 62] patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen.<br>[66, 73] Patients with bidimensionally measurable disease were randomised<br>[160, 167] A total of 226 patients were evaluable<br>[333, 345] group of patients receiving topotecan at relapse of ovarian cancer.

<br></td>
</tr>
